Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2- early breast cancer
Cancer Types
Lung Cancer
Real-world outcomes in patients with KRAS G12C-mutated advanced non-small cell lung cancer treated with docetaxel in second-line or beyond
Current Treatment Options in Oncology
Novel Estrogen Receptor-Targeted Agents for Breast Cancer
Clinical Cancer Research
Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101)
Gynecologic Oncology
DKK1 is a predictive biomarker for response to DKN-01: Results of a phase 2 basket study in women with recurrent endometrial carcinoma
Cancer Treatment Reviews
The evolving landscape of antibody-drug conjugates in gynecologic cancers
Journal of Clinical Oncology
Initial Evidence for the Efficacy of Naporafenib in Combination With Trametinib in NRAS-Mutant Melanoma: Results From the Expansion Arm of a Phase Ib, Open-Label Study
Clinical Advances in Hematology & Oncology
Novel endocrine therapy agents in ER-positive, HER2-negative breast cancer
Lancet
Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial
Journal for Immunotherapy of Cancer
First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817